Hydrocortisone dual release - ViroPharma Incorporated

Drug Profile

Hydrocortisone dual release - ViroPharma Incorporated

Alternative Names: Dual-release hydrocortisone; DuoCort™; Plenadren

Latest Information Update: 26 Mar 2015

Price : $50

At a glance

  • Originator DuoCort
  • Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenal insufficiency
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal insufficiency

Most Recent Events

  • 11 Mar 2014 ViroPharma is now called Shire ViroPharma
  • 24 Jan 2014 ViroPharma has been acquired by Shire
  • 22 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top